Pin22 Impact of S.AUREUS Infections on Expenditures and Length-of-Stay in U.S. Hospitals

Noskin, Gary A.; Rubin, Rita; Schentag, Jerome J.; Kluytmans, Jan; Hedblom, Edwin C.; Jacobson, Caron A.; Smulders, Maartje; Gemmen, EK; Bharmal, M

doi:10.1016/s1098-3015(10)69043-2

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The resulting effect of SA infection creates a significant financial burden and detrimentally impacts public health system around the world . Approximately half a million people acquire staphylococcal infections in the United States per year, and the cost of SA healthcare‐associated infections was estimated to exceed 14 billion US dollars in 2003 . Hence, there is an urgent need for the development of drugs as an alternative to antibiotic therapeutics or of biologics to be used in adjuvant therapy.…”

Section: Introductionmentioning

confidence: 99%

Preparation and identification of transfer factor specific to Staphylococcus aureus in vitro

Zhou

Chen

Wang

et al. 2014

Biotech and App Biochem

View full text Add to dashboard Cite

The objective of the study was to explore the methods for preparing transfer factor specific to Staphylococcus aureus (SA-STF) in vitro. Under the optimum conditions, the spleen cells of rabbits were immunized with SA in vitro to prepare SA-STF, and the immune activities were identified with the phagocytosis and sterilization, skin delayed-type hypersensitivity, and immune protection tests. The concentration of polypeptide was 2.26 ± 0.27 mg/mL, and ribose was 0.684 ± 0.094 mg/mL. The phagocytosis and sterilization rates of the STF group were 70.9 ± 12.4% and 62.1 ± 12.2%, respectively, and compared with the non-specific transfer factor (NTF) group, there were no significant differences (P = 0.074 and 0.069, respectively). The skin was inflamed and marked nodules formed at the injection site in the mice of the STF group rather than the NTF and control groups. The survival rate of the STF-1 group was significantly higher than the survival rates of the STF-2 (P = 0.024) and NTF groups (P = 0.016). SA-STF was prepared and characterized successfully in vitro, and it probably is a biological candidate for therapy or adjuvant therapy for diseases caused by Staphylococcus aureus.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and identification of transfer factor specific to Staphylococcus aureus in vitro

Zhou

Chen

Wang

et al. 2014

Biotech and App Biochem

View full text Add to dashboard Cite

show abstract

“…The bacterium is one of the most common causes of hospital‐acquired infections, and contraction of the infection, frequently following surgery, is associated with a fivefold increased risk of in‐hospital death . A 2003 study highlighted the exorbitant economic burden incurred by S. aureus infections, estimating that S. aureus ‐related healthcare cost amounted to $14.5 billion for inpatient stays and $12.3 billion for surgical patient stays in the U.S. alone . Prophylactic measures against the bacteria is thus of urgent need, particularly as antibiotic therapeutics are faced with increasing antidrug resistance.…”

Section: Challenges and Opportunities In Antibacterial Vaccinationmentioning

confidence: 99%

Advances and Opportunities in Nanoparticle‐ and Nanomaterial‐Based Vaccines against Bacterial Infections

Lin

Chattopadhyay

Lin

et al. 2018

Adv Healthcare Materials

View full text Add to dashboard Cite

As the dawn of the postantibiotic era we approach, antibacterial vaccines are becoming increasingly important for managing bacterial infection and reducing the need for antibiotics. Despite the success of vaccination, vaccines remain unavailable for many pressing microbial diseases, including tuberculosis, chlamydia, and staphylococcus infections. Amid continuing research efforts in antibacterial vaccine development, the advancement of nanomaterial engineering has brought forth new opportunities in vaccine designs. With increasing knowledge in antibacterial immunity and immunologic adjuvants, innovative nanoparticles are designed to elicit the appropriate immune responses for effective antimicrobial defense. Rationally designed nanoparticles are demonstrated to overcome delivery barriers to shape the adaptive immunity. This article reviews the advances in nanoparticle- and nanomaterial-based antibacterial vaccines and summarizes the development of nanoparticulate adjuvants for immune potentiation against microbial pathogens. In addition, challenges and progress in ongoing antibacterial vaccine development are discussed to highlight the opportunities for future vaccine designs.

show abstract

Pin22 Impact of S.AUREUS Infections on Expenditures and Length-of-Stay in U.S. Hospitals

Cited by 2 publications

References 0 publications

Preparation and identification of transfer factor specific to Staphylococcus aureus in vitro

Preparation and identification of transfer factor specific to Staphylococcus aureus in vitro

Advances and Opportunities in Nanoparticle‐ and Nanomaterial‐Based Vaccines against Bacterial Infections

Contact Info

Product

Resources

About